SST has a number of effects on the GI tract including inhibition of gastric acid secretion, pancreatic secretion and biliary secretion. It also reduces gatsric mucosal blood flow, gastric perfusion and stimulates mucus production. Octreotide has a similar secretory effect but it is unknown whether it elicits the same effect on the mucosa or blood flow.
The meta-analysis covering 14 RCTs show good evidence for the use of SST in acutely bleeding peptic ulcer to reduce the risk of continued bleeding, and a trend for reducing the need for surgery. The pH study and doppler studies theoretically support its use, as SST is shown to increase gastric pH (and thus allow optimum platelet function and decrease fibrinolysis) and decrease arterial blood flow, though with no date re clinical correlation.
The two octreotide studies included in the meta-analysis have completely different conclusions-the blinded trial showing no effect on outcome, the non-blinded trial concluded that octreotide stopped PU bleed, decreased Tx requirements and need for surgery. The further non blinded RCT by Archimandritis concluded that octreotide is not superior to ranitidine.
There were no published studies on the use of terlipressin.
In conclusion, there is an evidence base for the use of SST in severe, acute, non variceal peptic ulcer bleeding, but not for other vasoconstricors at present.
What is needed is a large study looking at the efficacy of SST in specific patient groups, defined by source of, and severity of bleeding (ie active/non bleeding visible vessel).
c CLINICAL BOTTOM LINE SST should be considered in unwell patients who are likely to be bleeding secondary to PUD until definitive endoscopy, or in situations when endoscopy is contraindicated or unavailable. There is no definitive evidence for the length of time treatment should continue. A short cut review was carried out to establish whether water soluble contrast small bowel follow through studies are useful in the management of patients with suspected adhesive small bowel obstruction (ASBO). In total, 152 papers were found using the reported search, of which 21 represented the best evidence to answer the clinical question. The clinical bottom line is that administration of oral contrast medium in patients with ASBO reduces the need for operation, hastens resolution of obstruction, and reduces length of hospital stay. Oral water soluble contrast follow through studies should be performed in patients presenting with ASBO who are not obvious candidates for immediate operative treatment.
Clinical scenario
A 65 year old woman is brought into the emergency department following a 3 day history of nausea and vomiting, abdominal distension, and absolute constipation. Her vital signs are stable, and his abdomen is distended but not tender. A lower midline laparotomy scar from a previous hysterectomy is noted. A plain abdominal radiograph shows distended loops of small bowel with a paucity of air in the colon. A clinical diagnosis of ASBO is made. You wonder whether a water soluble contrast small bowel follow through (SBFT) study would be useful in the management of a patient with presumptive ASBO. 
Outcome
In total,152 papers were found, of which 21 were relevant to the topic.
ASBO, adhesive small bowel obstruction, NS, not significant. Level of evidence: level 1 denotes that a recent wellperformed systematic review was considered or a study of high quality is available.
Comment(s)
Published literature strongly supports the use of water soluble contrast as a predictive test for non-operative resolution of adhesive small bowel obstruction. The evidence supports that amidotrizoate hastens resolution of small bowel obstruction and reduce length of hospital stay.
c CLINICAL BOTTOM LINE Administration of oral contrast medium in patients with ASBO reduces the need for operation, hastens resolution of obstruction and reduces length of hospital stay. Oral water soluble contrast follow through studies should be performed in patients presenting with ASBO who are not obvious candidates for immediate operative treatment. 
